[Form 4] Haemonetics Corporation Insider Trading Activity

Rhea-AI Filing Summary

Silvercrest Asset Management Group Inc. (Nasdaq: SAMG) filed a Form 8-K dated 25 Jul 2025 to announce logistics for its second-quarter earnings release. The company will issue Q2 2025 results and host a teleconference on 1 Aug 2025 at 8:30 a.m. ET. Details were disseminated via a press release, furnished as Exhibit 99.1. No financial figures, guidance, or operational updates are included in the filing. Management states the furnished information is not deemed “filed” under Exchange Act Section 18 and will not be incorporated by reference unless specifically stated in future filings.

Other exhibits are routine, including the Inline XBRL cover page (Exhibit 104). The filing is therefore informational, signaling the upcoming release rather than providing new performance data.

Insights

Sell-side Analyst

TL;DR: Neutral filing; only announces Q2 call, no metrics—little immediate impact.

Form 8-K simply schedules the Q2 2025 results call. Because no revenue, AUM, or EPS data are disclosed, investors receive no incremental insight into Silvercrest’s operating trajectory. The event may create a catalyst on 1 Aug when numbers drop, but today’s filing neither alters valuation models nor changes risk assessments. Impact classified as procedural.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Zane Ellen M

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2025		A		2,693(1)	A	(2)	19,373	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Ms. Zane	07/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

When will Silvercrest (SAMG) release its Q2 2025 earnings?

The company plans to report Q2 2025 results on 1 Aug 2025 and discuss them on a teleconference at 8:30 a.m. ET.

What type of document did Silvercrest file on 25 Jul 2025?

Silvercrest filed a Form 8-K to announce details of its upcoming earnings call.

Is any financial data included in this 8-K?

No. The filing contains no revenue, earnings, or AUM figures; it only furnishes the press release scheduling the call.

Where can investors find the related press release?

The press release is attached as Exhibit 99.1 to the Form 8-K filing.